This report is a market overview of GLP-1R agonists, focusing on their potential repurposing and label expansions in diseases outside type 2 diabetes and obesity.
The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties.
GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets.
Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.
The potential of GLP-1RAs is based on their insulin sensitization and anti-inflammatory properties.
GLP-1RAs are being investigated in different diseases in the metabolic, neurologic, and cardiologic markets.
Novo Nordisk and Eli Lilly are currently the major players in the GLP-1RA space, but opportunity remains for new entrants.
Scope
- Overview of GLP-1R agonists, including marketed GLP-1RAs and diseases under investigation.
- Analysis of unmet needs, challenges and opportunities in GLP-1RAs repurposing.
- Pipeline analysis and opportunity assessment of GLP-1RAs in different therapeutic areas.
- Overview of current major players in the GLP-1RAs space and potential future players.
- GLP-1RAs global market outlook and deals overview.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the GLP-1RAs therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GLP-1RAs therapeutics market in the future.
- Identify the major challenges and opportunities in the GLP-1RA space and the potential of this therapeutic class in multiple indications.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Preface
3 GLP-1R Agonists Overview
4 Industry Trends
5 Marketed Products
7 Pipeline Analysis
8 Opportunities and Challenges
9 Companies
10 Market Outlook and Deals
11 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Novo Nordisk AS
- Eli Lilly and Co
- Shanghai Minwei Biotechnology Co Ltd
- Metsera Inc
- Sihuan Pharmaceutical Holdings Group Ltd
- Hanmi Pharmaceuticals Co Ltd
- Jiangsu Hengrui Medicine Co Ltd
- AstraZeneca Plc
- PegBio Co Ltd
- Beijing QL Biopharmaceutical Co Ltd
- Sciwind Biosciences Co Ltd
- U.S. National Institutes of Health
- Boehringer Ingelheim International GmbH
- i2O Therapeutics Inc
- Zhejiang Doer Biologics Corp
- CSPC Pharmaceutical Group Ltd
- Peptron Inc
- Carmot Therapeutics Inc
- Amogen Pharma Pvt Ltd
- BioLingus AG
- The United Laboratories International Holdings Ltd
- Tonghua Dongbao Pharmaceutical Co Ltd
- Annovis Bio Inc
- ImmunoForge Co Ltd
- Biogenomics Ltd
- China Pharmaceutical University
- Zhejiang Heze Pharmaceutical Technology Co Ltd
- Zhuhai United Laboratories Co Ltd
- Hangzhou Jiuyuan Gene Engineering Co Ltd
- Structure Therapeutics Inc
- Altimmune Inc
- Chia Tai Tianqing Pharmaceutical Group Co Ltd
- Gmax Biopharm LLC
- Guangzhou Dazhou Biomedical Technology Co Ltd
- Hangzhou Zhongmei Huadong Pharmaceutical Co Ltd
- Huadong Medicine Co Ltd
- Innovent Biologics Inc
- Merck & Co Inc
- Neuraly Inc
- Onegene Biotechnology Inc
- Protheragen Inc
- RenaissThera Pvt Ltd
- Sekkei Inc
- Uni-Bio Science Group Ltd
- HEC Pharma Co Ltd
- Jiangsu Hansoh Pharmaceutical Group Co Ltd
- Cascade Pharmaceuticals Inc
- D&D Pharmatech Co Ltd
- Huons Global Co Ltd
- Immunwork Inc
- Leto Laboratories Co Ltd
- MetaVia Inc
- Pfizer Inc
- Qilu Regor Therapeutics Inc
- Sanofi
- Xintrum Pharmaceuticals Ltd
- Gan & Lee Pharmaceuticals Co Ltd
- Adocia SAS
- AnyGen Co Ltd
- Ascendis Pharma AS
- AULBIO Co Ltd
- BrightGene Bio-Medical Technology Co Ltd
- Camurus AB
- HK inno.N Corp
- Hybio Pharmaceutical Co Ltd
- IGC Pharma Inc
- Lancaster University
- Laxxon Medical GmbH
- Poolbeg Pharma Plc
- ProGen Co Ltd
- Septerna Inc
- Shanghai Innogen Pharmaceutical Technology Co Ltd
- Shenzhen Salubris Pharmaceuticals Co Ltd
- Sun Pharmaceutical Industries Ltd
- Suzhou Wingtech Pharmaceutical Technology Co Ltd
- Theertha Biopharma Pvt Ltd
- Verdiva Bio Ltd
- Vivani Medical Inc
- Yunovia Co Ltd
- Adare Pharma Solutions
- Amgen Inc
- Apeloa Pharmaceutical Co Ltd
- ApicHope Pharmaceutical Co Ltd
- Arecor Therapeutics Plc
- Biolexis Therapeutics Inc
- Biomea Fusion Inc
- Biomed Industries Inc
- BioNxt Solutions Inc
- California Institute for Biomedical Research
- China Medical System Holdings Ltd
- Chongqing Chenan BioPharm Co Ltd
- CinFina Pharma LLC
- Crinetics Pharmaceuticals Inc
- CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co Ltd
- Daewoong Therapeutics Inc
- Diabetology (Products) Ltd
- Dx&Vx
- Efil Bioscience Inc
- Entera Bio Ltd
- Gilead Sciences Inc
- Guangzhou BeBetter Medicine Technology Co Ltd
- HangZhou HuiSheng Biotech Pharmaceutical Co Ltd
- Hepagene Therapeutics Inc
- HighField Biopharmaceuticals, Inc.
- Hua Medicine Shanghai Ltd
- INVENT Pharmaceuticals Inc
- Inventage Lab Inc
- iX Biopharma Ltd
- Jiangsu Normal University
- Jiangsu Sinopep Allsino Biopharmaceutical Co Ltd
- Livzon Pharmaceutical Group Inc
- MeiraGTx Holdings Plc
- MindRank Ltd
- Niedlfree Technologies Pvt Ltd
- OPKO Health Inc
- Remedium Bio Inc
- Scohia Pharma Inc
- Shandong New Era Pharmaceutical Co Ltd
- SN BioScience Co Ltd
- Tharimmune Inc
- Viking Therapeutics Inc
- vTv Therapeutics Inc
- Youngene Therapeutics Co Ltd
- Zealand Pharma AS
- 4Moving Biotech
- Abaxys Therapeutics SA
- Aerami Therapeutics Holdings Inc
- AI Proteins Inc
- Akrikhin
- Alphamab Oncology
- Aprilbio Co Ltd
- Ascletis Pharma Inc
- Beijing Eastern Biotech Co Ltd
- Beijing SL Pharmaceutical Co Ltd
- Biora Therapeutics Inc
- Bostal Drug Delivery Co Ltd
- Bristol-Myers Squibb Co
- Chengdu Brilliant Pharmaceutical Co Ltd
- China Resources Double-Crane Pharmaceutical Co Ltd
- Closed Loop Medicine Ltd
- Coya Therapeutics Inc
- Delpor Inc
- Duke University
- Enteris BioPharma Inc
- G2GBIO Inc
- GlyTech Inc
- Gubra ApS
- Halo Therapeutics Ltd
- HEC Pharm Group
- Hualan Biological Engineering Inc
- Iconovo AB
- Icure Pharmaceutical Inc
- Imagine Pharma LLC
- Immupharma Plc
- Imperial College London
- Innopharmax Inc
- Jiangsu Wanbang Biochemical Pharmaceutical Group Co Ltd
- Kailera Therapeutics Inc
- Kariya Pharmaceuticals IVS
- Kunming Yinnuo Medical Technology Co. Ltd.
- Lanzhou Institute of Biological Products Co Ltd
- Lepu Medical Technology (Beijing) Co Ltd
- Mapi Pharma Ltd
- MBX Biosciences Inc
- Metaphore Biotechnologies Inc
- Nanexa AB
- National Institute of Biomedical Imaging and Bioengineering
- NutriBand Inc
- Oramed Pharmaceuticals Inc
- Original BioMedicals Co Ltd
- Pep2Tango Therapeutics Inc
- ProLynx LLC
- Qilu Pharmaceutical Co Ltd
- QuiaPEG Pharmaceuticals AB
- Rani Therapeutics LLC
- Rivus Pharmaceuticals Inc
- Rose Pharma Inc
- R-Pharm
- Sail Biomedicines Inc
- Shandong Boan Biotechnology Co Ltd
- Shanghai Fosun Pharmaceutical (Group) Co Ltd
- Sino Biopharmaceutical Ltd
- Syracuse University
- Terns Pharmaceuticals Inc
- Terry Suzhou Pharmaceutical Co Ltd
- The University of Adelaide
- Twist Bioscience Corp
- University of Padova
- University of Ulster
- Vanderbilt University
- Virtici LLC
- Wuxi Hebang Biotechnology Co Ltd
- Yichang Humanwell Pharmaceutical Co Ltd
- Yonsei University College of Medicine
- Zhejiang HuaYang Pharmaceutical Co Ltd
- Zhongshan Wanhan Pharmaceutical Co Ltd